source
- Voyager Therapeutics CEO Al Sandrock to resign next year, remains on board; Insmed appoints Paul Hudson as directorVoyager Therapeutics announced that its chief executive, Al Sandrock, will step down in the first quarter of next year. Sandrock will continue to serve on Voyager's board after his resignation, pr…
- Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStarGilead Sciences has picked up a new inflammatory disease program from China’s PepStar Therapeutics to pair with the Phase 2 inflammatory bowel disease asset emvistegrast.BioSpace · 20d ago↗ source
- FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns